Yervoy Safety Profile & Adverse Events

Safety Profile Overview

Anti-CTLA-4 checkpoint inhibitor, the first approved in its class for melanoma. Significant immune-mediated adverse event profile.

Generic Name

ipilimumab

Brand Names

Yervoy

Therapeutic Class

CTLA-4 Inhibitor

Manufacturer

Bristol-Myers Squibb

What Pharma Signal Tracks for Yervoy

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Yervoy, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Yervoy products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Yervoy Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Yervoy.

curl "https://api.pharma-signal.com/drug/safety/yervoy" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Yervoy against other CTLA-4 Inhibitor drugs, or explore the full manufacturer portfolio for Bristol-Myers Squibb.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Yervoy ranks within CTLA-4 Inhibitor on serious event rates.
Company portfolio risk — View all drugs from Bristol-Myers Squibb with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.